Medicaid Cuts: Impact on U.S. Children’s Health
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated critically important weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. However, it’s crucial to note that the trial did *not* meet its primary endpoint of reducing MACE, despite the significant weight loss observed in the semaglutide group (an average of approximately 15% of body weight).
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Major Adverse Cardiovascular Event (MACE) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.0 | 2.2 | 1.35 |
| non-Fatal Stroke | 1.7 | 1.3 | 1.31 |
| Non-Fatal Heart Attack | 2.5 | 1.9 | 1.32 |
Who is Affected? Understanding the Patient Population
The SELECT trial specifically enrolled individuals with a body mass index (BMI) of 27 or higher *and* established cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery disease. This is a critical distinction. The findings do *not* necessarily apply to individuals using semaglutide for weight loss who do not have pre-existing heart conditions. However, the results raise concerns about the potential for increased risk in this vulnerable population.
It’s also critically important to consider that the participants were already receiving standard cardiovascular care, including medications like statins and antiplatelet drugs. The added risk observed with semaglutide occurred *despite* this baseline treatment.
Why Does This Matter? The Implications for Clinical Practice
The SELECT trial challenges the widely held belief that semaglutide is a safe and effective treatment for obesity,regardless of cardiovascular status.The observed increase in cardiovascular events suggests that the drug’s benefits may be outweighed by its risks in certain patients. This necessitates a more cautious and individualized approach to prescribing semaglutide.
Clinicians should carefully assess patients’ cardiovascular risk factors before initiating semaglutide therapy.Those with established heart disease should be closely monitored for any signs of cardiovascular complications.Moreover, patients should be fully informed about the potential risks and benefits of the drug.
Timeline of Events & Key Developments
- August 2023: